Becton Dickinson & Co

23% decline in Becton Dickinson shares over three years shows investor pain, yet the company’s large market cap and R&D push still offer potential upside.

Becton Dickinson & Co. achieves industry milestone by becoming the first medical technology company to earn a diamond-level rating in supply chain resilience across all seven domains.

Becton Dickinson & Co’s stock price has stabilized at $176.37, reflecting a moderate valuation and investor confidence in the company’s future growth prospects in the health care sector.

Becton Dickinson & Co.’s stock performance and valuation metrics raise concerns about the company’s stability and value, highlighting the need for a critical examination of its financial strategy and market position.

Becton Dickinson & Co has announced a groundbreaking merger with Waters’ Biosciences & Diagnostic Solutions division, creating a $40 billion market leader in biotechnology and diagnostics.

Becton Dickinson & Co. reported a fiscal second-quarter earnings beat, surpassing Wall Street expectations despite a revenue miss, and updated its fiscal 2025 guidance with a cautiously optimistic outlook.

Becton Dickinson & Co. reports strong Q1 2025 earnings, with robust revenue growth and a market capitalization of $58.7 billion USD, solidifying its position as a leader in the health care equipment and supplies industry.